Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
Investing.com - CFRA upgraded GlaxoSmithKline (NYSE:GSK) from Hold to Buy and raised its price target to $53.00 from $40.00 following the pharmaceutical company’s strong third-quarter performance. The stock has delivered impressive returns, with a 40.4% gain year-to-date and is currently trading near its 52-week high of $46.87.
The research firm cited better-than-expected execution and a guidance upgrade that sits at the upper end of the peer range as key factors behind the rating change. The new target price implies a 2026 price-to-earnings ratio of 10.7x, higher than GSK’s three-year average of 9.3x. According to InvestingPro data, GSK appears undervalued based on its Fair Value assessment, with analysts having revised earnings upwards for the upcoming period.
CFRA adjusted its earnings per American Depositary Share estimates to £3.40 from £3.30 for 2025 and to £3.76 from £3.70 for 2026, reflecting the company’s improved guidance. The company’s current diluted EPS stands at $1.13 for the last twelve months, with forecasts expecting $2.18 for fiscal 2025.
The firm expressed optimism about GSK’s Specialty Medicines segment, noting continued demand and new product launches. The recent approval of Blenrep was viewed positively despite being narrower than initially anticipated, especially following July’s FDA advisory setback that pressured the share price.
CFRA balanced its optimistic outlook by acknowledging several challenges facing GSK, including weakness in its Vaccines business, a delay in a key HIV treatment trial, and ongoing execution risks.
In other recent news, GSK plc reported strong third-quarter 2025 earnings, significantly surpassing analyst expectations. The company achieved an earnings per share (EPS) of $1.46, compared to the forecasted $1.26. Additionally, GSK’s revenue reached $11.35 billion, exceeding predictions of $11.01 billion. These financial results highlight the company’s robust performance in the recent quarter. While the earnings beat has been noteworthy, there are no updates on mergers or acquisitions at this time. Analyst upgrades or downgrades have not been reported in the latest developments. Investors will be keen to see how GSK continues to perform in the coming quarters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.